INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

VNDAVanda Pharmaceuticals Inc.

CIK 0001347178

EDGAR filingsOpen in network
Disclosed transactions1
Buys / sells0 / 0
Max Insider Score9
Connections3with evidence

VNDA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
DC
Duncan Charles CliffDirector
VNDAVanda Pharmaceuticals Inc.
Grant or award
A—
57.1K sh
Apr 22, 2026Apr 24, 2026
traded Apr 22, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    MANATOS & MANATOSLDA Q2 2026 second quarter · Pharmacy · Aug 26, 2026
  • ← Insider ofevidence
    Duncan Charles CliffDirector · Apr 24, 2026

Lobbying

$0 reported · de-duplicated
2026 Q2 $0 via firms2026 Q1 $0 via firms
  • MANATOS & MANATOS—2026 Q1 · posted Aug 26, 2026 · Pharmacy
  • MANATOS & MANATOS—2026 Q2 · posted Aug 26, 2026 · Pharmacy

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.